Metformin to Reduce Heart Failure After Myocardial Infarction

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

Also called NCT01217307

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 380 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01217307
Other papers using this trial's data
  • Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction Journal of the American College of Cardiology, 2021-10-05 DOI, PubMed 34593124
  • Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial PloS one, 2016 DOI, PubMed 26808474, PMC4726568 In the PMC Open Access subset under CC BY.
  • Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction Circulation. Cardiovascular genetics, 2017-02 DOI, PubMed 28100626
  • Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial JAMA, 2014-04-16 DOI, PubMed 24687169
  • Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT Clinical research in cardiology : official journal of the German Cardiac Society, 2017-12 DOI, PubMed 28755285, PMC5696505 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01217307. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2018-01-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin to Reduce Heart Failure After Myocardial Infarction
Acronym
GIPS-III
Condition
ST Elevation Myocardial Infarction (STEMI)
Condition
Heart Failure
Condition
Diabetes
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo
Lead sponsor
University Medical Center Groningen (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)

Record details

Record id
cardio:ct-nct01217307
Content hash
ca1b272150a6f2ac648fabd39712f61ddfab1121d5a7ca41e76033977d981fee